A Multicenter 26-Week Extension study to evaluate the safety and clinical effects of prolonged exposure to 1 and 2 mg doses of EVP-6124 in alpha-7 nicotinic acetylcholine receptor agonist as an adjunctive procognative treatment in subjects with schizophr
|Effective start/end date||11/1/13 → 10/30/15|
- ENVIVO PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.